356 related articles for article (PubMed ID: 28270436)
1. Focal Adhesion Kinase as a Potential Target in AML and MDS.
Carter BZ; Mak PY; Wang X; Yang H; Garcia-Manero G; Mak DH; Mu H; Ruvolo VR; Qiu Y; Coombes K; Zhang N; Ragon B; Weaver DT; Pachter JA; Kornblau S; Andreeff M
Mol Cancer Ther; 2017 Jun; 16(6):1133-1144. PubMed ID: 28270436
[TBL] [Abstract][Full Text] [Related]
2. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
[TBL] [Abstract][Full Text] [Related]
3. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
[TBL] [Abstract][Full Text] [Related]
5. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
6. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
8. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
Roversi FM; Cury NM; Lopes MR; Ferro KP; Machado-Neto JA; Alvarez MC; Dos Santos GP; Giardini Rosa R; Longhini AL; Duarte ADSS; Pericole FV; Favaro P; Yunes JA; Saad STO
J Cell Mol Med; 2019 Feb; 23(2):1562-1571. PubMed ID: 30484958
[TBL] [Abstract][Full Text] [Related]
10. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
Mehta SV; Shukla SN; Vora HH
Neoplasma; 2013; 60(6):666-75. PubMed ID: 23906301
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
13. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
15. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis.
Recher C; Ysebaert L; Beyne-Rauzy O; Mansat-De Mas V; Ruidavets JB; Cariven P; Demur C; Payrastre B; Laurent G; Racaud-Sultan C
Cancer Res; 2004 May; 64(9):3191-7. PubMed ID: 15126359
[TBL] [Abstract][Full Text] [Related]
16. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
[TBL] [Abstract][Full Text] [Related]
17. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
Bourrié B; Brassard DL; Cosnier-Pucheu S; Zilberstein A; Yu K; Levit M; Morrison JG; Perreaut P; Jegham S; Hilairet S; Bouaboula M; Penarier G; Guiot C; Larroze-Chicot P; Laurent G; Demur C; Casellas P
Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
[TBL] [Abstract][Full Text] [Related]
18. IRAK1: oncotarget in MDS and AML.
Beverly LJ; Starczynowski DT
Oncotarget; 2014 Apr; 5(7):1699-700. PubMed ID: 24880611
[No Abstract] [Full Text] [Related]
19. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
[TBL] [Abstract][Full Text] [Related]
20. Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered Wnt signaling.
Despeaux M; Chicanne G; Rouer E; De Toni-Costes F; Bertrand J; Mansat-De Mas V; Vergnolle N; Eaves C; Payrastre B; Girault JA; Racaud-Sultan C
Stem Cells; 2012 Aug; 30(8):1597-610. PubMed ID: 22714993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]